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open access at premium prices. Treatments with moderate value have been pro-
vided quick access to patient sub-populations; with access increasing as prices
dropped. Treatments with low incremental value have either had to launch at
competitive prices or faced delays or significant restrictions to reimbursement till
prices dropped. While countries have used different methodologies of assessment,
the outcomes have been strikingly similar. This provides important lessons for
emerging markets. Currently many markets use blunt instruments such as across
the board price controls, which impede effective access. We posit three principles
that can help emerging markets provide effective access to medicine. First, they
must use HTA to prioritise medicines. Second, this prioritization must inform re-
source allocation. Third, they can leverage the analysis and rationale from this
prioritization and budget allocation to inform negotiations with manufacturers,
which should be based on the three levers identified above – time to reimburse-
ment, level of access and price.
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OBJECTIVES: It is extremely challenging to keep up to speed with the perpetually
dynamic Market access environment across different countries. This is difficult not
only for pharma but for payers who have the difficult task of assessing products
under tight budgetary constraints. This research is to understand the drivers influ-
encing pricing and market access decisions. METHODS: The research was con-
ducted through in-depth secondary research and interviews with stakeholders in 8
countries including the UK, Japan, Canada, France, Germany, Australia, S. Korea,
Sweden and The Netherlands. RESULTS: Analysis indicates that the value of drugs
varies by market globally due to factors of prevalence, socio-economic conditions,
unmet need, disease severity, political impact and public awareness. These factors
lead to differences in the perceived value of the same drug across countries making
it challenging for its global launch. The research indicated that most countries,
other than those that apply external price referencing use some form of value
assessment to recommend the price and reimbursement. In most mature markets
therapeutic gain measured through clinical advancement or cost effectiveness is
the critical factor. In addition these countries consider unmet needs and disease
severity as important drivers. In Sweden and the Netherlands, they consider soci-
etal perspective and Japan and Korea tend to give importance to innovation. The
only value element that does not directly relate to clinical factors and is influential
in setting the price is budget impact. CONCLUSIONS: The research indicated that
most countries, other than those that use international price referencing for setting
prices use some form of value assessment method before fixing the reimbursement
level and price of a product. It is very challenging to reward products based on their
intrinsic value without considering the current economic situation. On the contrary
innovation needs to be rewarded and encouraged for future R&D of new drugs.
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OBJECTIVES: With the increasing financial constraints facing health care systems,
innovative pricing and reimbursement schemes between payers and pharmaceu-
tical manufacturers are frequently discussed as a means of addressing the uncer-
tainty and financial concerns faced by both parties. The objectives of this study
were to review innovative pharmaceutical pricing and reimbursement schemes
across global markets and to quantify their occurrence over time. METHODS: The
literature search included two components: a search of published literature on
pharmaceutical pricing and reimbursement schemes performed in PubMed/MED-
LINE and a search of “grey” or unpublished literature conducted via the Internet.
Search terms used included “patient access schemes” and “risk-share agree-
ments”. Identified schemes were classified by country, payer, therapeutic area,
indication, drug, year, type (financial or outcomes-based) and structure (e.g., cov-
erage with evidence development). Where applicable, multiple sources were used
to obtain a full picture of a specific scheme. RESULTS: A total of 225 schemes were
identified between 1994 through 2011. 38% of the schemes were from the UK,
followed by Italy (16%) and the United States (11%). 48% of the schemes were
classified as outcomes-based and 49% as financial-based (49%). The number of
schemes identified per year remained under 10 until 2007, when 27 were identified.
The number of schemes peaked in 2009 with 33, decreasing to 17 in 2010 and 13 in
2011. Schemes for oncology products comprised 50% of all identified schemes,
followed by neurology and musculoskeletal products (10% each). Within outcomes-
based schemes, 46.2% were classified as conditional coverage and 40.5% as perfor-
mance-based reimbursement. CONCLUSIONS: Pricing and reimbursement
schemes such as risk-share agreements appear to be most frequently used in on-
cology. The UK had the most schemes per country, likely as a result of the inclusion
of patient access schemes in the NICE process. Understanding the landscape of
existing schemes can potentially aid in developing new schemes.
PODIUM SESSION I:
RESEARCH ON QUALITY OF LIFE AND PATIENT PREFERENCE METHODS
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OBJECTIVES: The latest EQ-5D instrument, EQ-5D-5L, needs new country-specific
valuation studies to obtain a value set. Eight countries have participated on pilot
exercises to develop a final protocol. Spain is the first country where this protocol
was introduced as part of the EuroQol Valuation Project. In this presentation we
report a descriptive overview of EQ-5D-5L Spanish valuation methodology and its
preliminary results. METHODS: The survey has a two-stage sampling plan. The
first stage concentrates on the selection of Spanish regions. The 50 Spanish regions
were ordered by population size, and the first 20 regions covering 80% of the total
Spanish population were selected. In the second stage, a simple random sampling
strategy on each of the selected regions was conducted. The sample size on each
region was calculated multiplying the total sample size (1,000) by the percentage of
the population on the region respect the total population of the select 20 regions.
The final survey has three blocks of questions. The first block includes patient
characteristics (age, gender and socioeconomic status), and a respondent valuation
of own health using the EQ-5D-5L. The second block contains 10 composite time
trade-off (TTO) questions, using classic TTO for states better than death and “Lead
Time” TTO for health states considered worse than death. The last block contains
7 Discrete Choice experiment questions, where the participant has to choose be-
tween two states. Finally some questions about the difficulties of the survey are
also included. RESULTS: A detailed overview of summary statistics for the health
state valuations will be included. In addition, the impact of number of respondent
characteristics on health state valuation will also be explored. Different models
will be explored, hybrid TTO and DC model and conditional logit rescaled with TTO
values were used and compared. CONCLUSIONS: We obtained a Spanish Value set
for EQ-5D-5L.
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OBJECTIVES: Patient-relevant outcomes are an important aspect in treatment of
Parkinson’s disease (PD), which is a common progressing neurodegenerative dis-
ease. Data on minimal clinically important differences (MCIDs) in HrQoL-measures
in PD are limited for disease-specific scales (e.g. Parkinson’s Disease Question-
naire/PDQ-39) and not available for generic HrQoL scales, such as the EuroQol. The
objective was to assess the minimal clinically important differences for the PDQ-39
and the EuroQol in patients with PD. METHODS: HrQoL data were collected from
137 consecutively recruited patients with idiopathic PD. A range of MIDs for the
PDQ-39 and the EuroQol (EQ-5D index score and visual analogue scale/VAS) was
estimated using both anchor-based and distribution-based (1/2 standard deviation
and standard error of the measure) approaches. Groups were anchored using the
quintiles of the PDQ-39, the Unified Parkinson’s Disease Rating Scale (UPDRS) and
Beck Depression Inventory (BDI). RESULTS: For EQ-5D scores, MCIDs estimated
based on the PDQ-39 and the UPDRS were 0.11 (range: 0.08 to 0.14) and 0.10 (range:
0.04 to 0.17), respectively. MCIDs for VAS scores were 5.23 (range: 3.95 to 6.44, based
on the PDQ-39) and 5.23 (range: 0.55 to 10.96, based on the UPDRS). For the PDQ-39,
MCID estimated based on the UPDRS and BDI were 7.74 (range: 3.95 to 11.51) and
7.87 (1.95 to 11.74), respectively. Distribution based MCIDs ranged from 0.09 to 0.10
(EQ-5D score), from 9.01 to 11.40 (VAS score) and from 5.79 to 8.72 (PDQ-39).
CONCLUSIONS: We identified the minimum magnitude of change that should be
considered when conducting studies to evaluate change in HrQoL of PD patients
over time. These data on minimal clinically important differences are necessary for
estimation of sample size in clinical trials, which use HrQoL as outcome measure.
Further studies are encouraged to estimate MCIDs in HrQoL outcome measures in
neurodegenerative diseases.
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OBJECTIVES: Health Related Quality of Life (HRQoL) is a useful outcome variable in
chronic patients follow-up. Adaptive Measurement of Change (AMC) is a technique
to measure changes at the individual level in Computer Adaptive Tests (CATs)
based on Item Response Theory. The CAT-Health system is a recently developed
CAT which measures generic HRQoL. Using AMC the CAT-Health could be used to
assess changes in a follow-up for an individual patient, something currently not
possible with the available tools. The objective was to assess, by means of simula-
tion technique, the feasibility of using AMC as a stop rule for the CAT-Health
system when doing follow-ups. METHODS: A Montecarlo simulation of the re-
sponses from 700 subjects of varying levels of HRQoL at baseline and a follow-up
with a small change in the true score of the subject (6.25 points in a 0-100 scale,
5010). The first application used the CAT Health system usual stop rules: at least
5 items, at most 15, S.E. below 1 and not being reduced more than 5%. The second
application configured the system to stop if a significant change were detected.
RESULTS: The follow-up application mean length was 16.52 items. Excluding the
most healthy subjects (not in the target population), mean length was 15.02 items.
For this sample, 75.4% of the individual changes were detected, 68% with less than
25 items.CONCLUSIONS: Increasing the maximum length of the test to 25 items for
follow-ups we can theoretically detect most changes in the HRQoL of chronic pa-
tients.
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